All In MedTech

Device Trial Radar · NCT05650021

Rectal Spacer for Prostate Cancer Radiation Image Guidance

Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

17

Actual

Start

Mar 8, 2024

Primary completion

Sep 15, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
Milton S. Hershey Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 14, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if a radiopaque hydrogel rectal spacer, SpaceOAR Vue®, can be used in place of fiducial markers when aligning patients for radiotherapy. The investigator hypothesizes that the alignment of the patient based on the rectal spacer will be similar to the alignment of the patient with fiducial markers.

Conditions

  • Prostate Cancer

Interventions

  • SpaceOAR VueDevice

    CBCT images acquired during the first five fractions of radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in 3-dimensional Shifts Between Fiducial Marker and SpaceOAR Vue AlignmentTime frame: First through fifth radiotherapy fractions, occurring within 14 days after the first fraction.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Penn State Cancer Institute

    Hershey, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.